Kura Oncology, Inc. , a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States.
Kura Oncology stock last closed at $9.05, down 0.98% from the previous day, and has increased 50.08% in one year. It has overperformed other stocks in the Biotechnology industry by 0.63 percentage points. Kura Oncology stock is currently +66.06% from its 52-week low of $5.45, and -27.54% from its 52-week high of $12.49.
At the moment, there are 88.33M shares of KURA outstanding. The market value of KURA is $799.38M. In the past 24 hours, 875,000 KURA shares were traded.
How to Buy Kura Oncology Stock
Wondering how to invest in Kura Oncology stock? Here's how.
Choose where to buy Kura Oncology stock: You need to decide on a stock brokerage, but don't worry - we've sifted through dozens of stock brokerages and apps to help you decide where to buy Kura Oncology stock.
Sign up for your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
Fund your investment account: Select your method of payment and add your details.
Research Kura Oncology stock: The Kura Oncology ticker symbol is KURA. Is Kura Oncology stock a good investment? Should you buy shares of KURA? How do KURA's underlying business fundamentals look? Do top analysts think Kura Oncology is a good buy? Why has KURA's stock price moved recently? (Hint: Our stock market analysis tools can help you understand if KURA is a good stock to buy).
Place your KURA purchase: Decide if you will purchase KURA shares at the current market price or use a limit order to buy KURA shares at a specific price.
Monitor your KURA position: Create a watchlist to get the latest news on your position in Kura Oncology stock.
Step 1: Choose where to buy Kura Oncology stock
You need an online brokerage account in order to access the NASDAQ market and buy KURA stock.
A brokerage account enables you to buy and sell a number of investments, such as stocks, bonds, mutual funds, and ETFs.
Our favorite brokerage: eToro
Based on our analysis, eToro is the best brokerage. eToro gives you:
You can invest in stocks with 0% commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
Access to global financial markets: From Technology to Industrials, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of other investors.
Security: eToro is a regulated and licensed brokerage platform.
Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by signing up for an account with eToro today. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Sign up for your brokerage account
Now that you've selected your brokerage, you'll need to fill out some personal details so you can buy KURA today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Research Kura Oncology stock
Once you have figured out the best place to buy Kura Oncology stock, it's very important to analyze their stock before you invest, so you actually wrap your head around the risk as well as the upside.
Kura Oncology stock data
KURA Price
$9.05
1w %
2.96%
1y %
50.08%
5y %
-69.29%
P/E
-2.85x
P/B
4.59x
P/S
11.75x
PEG
N/A
Revenue
$67.48M
Earnings
-$278.67M
Fore. Rev. Growth
54.56%
Fore. Earn. Growth
N/A
Market Cap
$799.38M
Next Earnings
Apr 30, 2026
Next Dividend
N/A
KURA Fundamentals
WallStreetZen was created to help everyday investors perform more in-depth fundamental analysis.
There are more short-term assets than short-term liabilities on the KURA balance sheet.
KURA has $667.24M in cash and short term investments. This is enough to cover its annual cash burn of $70.70M.
KURA has cash burn of 70696000. It has sufficient cash and short-term investments to cover this for at least one year.
There are more short-term assets than long-term liabilities on the KURA balance sheet.
Failed Financial Due Diligence Checks:
Total KURA debt is higher than 5 years ago, relative to shareholder equity.
KURA profit margin has gone down from -322.9% to -412.9% in the past year.
KURA has a relatively high debt to equity ratio of 3.24.
Is KURA stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 7 Equities analysts who monitor KURA, the consensus analyst rating on KURA is a Strong Buy
Please keep in mind that analyst ratings are not recommendations, nor are they financial advice.
Most Recent KURA Analyst Upgrades/Downgrades
Joseph Pantginis, a top 8% analyst from HC Wainwright & Co. reiterates KURA with a buy rating and maintains their KURA price target from $40.00 to $40.00, on Jan 13, 2026.
Etzer Darout, a top 2% analyst from Barclays maintains KURA with a strong buy rating and raises their KURA price target from $11.00 to $28.00, on Nov 24, 2025.
Barclays's Etzer Darout raised their price target on Kura Oncology (NASDAQ: KURA) by 154.5% from $11 to $28 on 2025/11/24. The analyst maintained their Strong Buy rating on the stock.
On 2025/11/13, Kura Oncology announced that the U.S. FDA fully approved its KOMZIFTI™ (ziftomenib) treatment for adult patients with relapsed or refractory acute myeloid leukemia.
Darout said their price target hike was catalyzed by the approval.
Reni J. Benjamin, a top 23% analyst from JMP Securities reiterates KURA with a buy rating and maintains their KURA price target from $24.00 to $24.00, on Oct 20, 2025.
Last year, KURA revenue was $67.48M. In the last 1 years, KURA's revenue has increased by 25.24% per year. This was slower than the Biotechnology industry average of 27.11%.
No, Kura Oncology doesn't provide an income stream by paying out dividends.
What others are saying about KURA
One of the major reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other traders have to say.
Step 5: Place your KURA purchase
There are two primary order types:
Market order: A market order is an order to buy or sell a security at the best possible price. Market orders are mostly the best for newer investors.
Limit order: A limit order lets you buy or sell a security at a specific price (or better). If you want to make sure you're buying or selling at a specific price, use a limit order.
Click the Open button and eToro will execute your order.
If you want additional help with investing in stocks on eToro, click the helpful video below:
How much does it cost to buy one Kura Oncology share?
As of Apr 15, 2026, it costs $9.05 to buy one share of Kura Oncology stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $4, you can buy 0.442 shares of KURA.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.